0173698 - UEM-P 20033015 RIV NL eng J - Článek v odborném periodiku
Kulvik, M. - Vahatalo, J. - Buchar, Evžen - Farkkila, M. - Jarviluoma, E. - Jaaskelainen, J. - Kříž, O. - Laakso, J. - Rasilainen, M. - Kallio, M.
Clinical implementation of 4-dihydroxyborylphenylalanine synthesised by an asymetric pathway.
European Journal of Pharmaceutical Sciences. Roč. 18, - (2003), s. 155-163. ISSN 0928-0987. E-ISSN 1879-0720
Výzkumný záměr: CEZ:AV0Z5039906
Klíčová slova: Boron neutron capture therapy
Kód oboru RIV: FR - Farmakologie a lékárnická chemie
Impakt faktor: 2.248, rok: 2003

Boron neutron capture therapy (BNCT) is an experimental therapeutic modality combining a boron pharmaceutical with neutron irradiation. 4-Dihydroxyborylphenylalanine (L-BPA) synthesised via the novel pathway was developed to be boron containing pharmaceutical in the first series of clinical trials. Prior to starting clinical trials the acute toxicity of L-BPA was studied in male albino Sprague- Dawley rats. In accordance with earlier studies no adverse effect were observed.
Trvalý link: http://hdl.handle.net/11104/0001460